http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL
MONTREAL, Oct. 15 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it is undertaking a public offering in the United States of 5,250,000 shares of its common stock. Akela has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares at the public offering price to cover over-allotments, if any. Proceeds from the offering will be used to further the research, development and expansion of Akela's product candidates and for other working capital and general corporate purposes.
Akela has applied to list its common shares on the NASDAQ(TM) Global Market under the symbol "AKLA." Akela's shares are currently listed on the Toronto Stock Exchange under the symbol "AKL."
Lazard Capital Markets LLC will act as the sole book-running manager for the offering. Oppenheimer & Co., Inc. and Broadpoint Capital, Inc. will act as co-managers for the offering. A copy of the preliminary prospectus may be obtained by contacting Lazard Capital Markets LLC at 30 Rockefeller Plaza, New York, New York 10020, Attention: Syndicate Department, 60th Floor, or by phone at (212) 632-6717.
A registration statement relating to these securities has been filed
with the U.S. Securities and Exchange Commission but has not yet become
effective. These securities may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or a solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or jurisdict
'/>"/>
| SOURCE Akela Pharma Inc. Copyright©2007 PR Newswire. All rights reserved |